Asimov vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mammalian Cell Engineering Platform for Biologics & Gene Therapy
Asimov develops software and AI tools for mammalian cell engineering to accelerate design and manufacturing of biologics and gene therapies; combines synthetic biology, biophysical simulation, and machine learning;
About
Asimov is a Boston-based biotechnology and computational biology company founded in 2017 by Alec Nielsen, Raja Srinivas, and Christopher Voigt. The company's mission is to apply software engineering principles to cell engineering — treating genetic circuits in mammalian cells the way software engineers treat code. Asimov builds computational tools and AI models that predict how genetic constructs will behave in mammalian cells, enabling researchers to design, simulate, and optimize biologics and gene therapy vectors before conducting expensive wet lab experiments.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.